Market Overview

UPDATE: J.P. Morgan Initiates PennyMac Financial Services at Neutral on Current Uncertainty


In a report published Monday, J.P. Morgan analyst Richard Shane initiated coverage on PennyMac Financial Services (NYSE: PFSI) with a Neutral rating and $21.00 price target.

In the report, J.P. Morgan noted, “We are initiating coverage of PennyMac Financial Services with a Neutral rating and a $21 price target (December 2013). We believe the current share price reflects uncertainty in the residential mortgage sector and PFSI's growth potential. We expect that higher rates and wider mortgage spreads may dampen volumes and compress margins. We think the market environment reduces earnings visibility and increases volatility. Long-term, we believe PFSI is building an attractive platform for the origination and servicing of residential mortgages, and that the platform is designed to be dynamic as government support of the mortgage markets recedes.”

PennyMac Financial Services closed on Friday at $21.80.

Latest Ratings for PFSI

Sep 2019MaintainsOverweight
Sep 2019UpgradesMarket PerformOutperform
Aug 2019MaintainsNeutral

View More Analyst Ratings for PFSI
View the Latest Analyst Ratings

Posted-In: J.P. Morgan Richard ShaneAnalyst Color Initiation Analyst Ratings


Related Articles (PFSI)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Forbes Columnist Gordon Chang Explains Why China Has It Wrong

Keryx Biopharma Says Zerenex Met Primary, Secondary Endpoints